Latest
Mutations Associated With Disseminated Intravascular Coagulation in Acute Leukemia
No Change in Transplant Outcomes for DLBCL With Addition of Rituximab to Conditioning
Richter Transformation Survival in CLL Appears Better Among Treatment-Naive
Thromboembolism Incidence With Splenectomy for Automimmune Hemolytic Anemia
Ruxolitinib May Be Effective for Reducing Spleen Length in Patients With Myelofibrosis
Radotinib May Have Similar Efficacy to Imatinib in Chronic Myeloid Leukemia
Intensive Immunochemotherapy May Yield Positive Outcomes in Burkitt Lymphoma
Chemotherapy-Induced Nausea Prevention With Olanzapine Plus Standard Antiemetic Therapy
Low-Dose Direct-Acting Oral Anticoagulants Cost-Effective for Thrombosis Prevention in Cancer
Best Practices for Diagnosing Breast Implant-Associated Anaplastic Large Cell Lymphoma
Intestinal Microbiota Composition and Bloodstream Infection in Stem Cell Transplant Recipients
Single-Agent Daratumumab May Delay Progression of Smoldering Multiple Myeloma
Featured Content
New ASH Clinical Guidelines on Transfusion Support for Sickle Cell Disease
A panel of researchers developed evidence-based guidelines to support clinical decision making regarding transfusion support for patients with sickle cell disease.
Managing Complications Associated With Increased Longevity in Beta Thalassemia
As the life expectancy for patients with beta thalassemia continues to increase, more and more patients are experiencing age-related complications.
Peripheral Neuropathy Complicates Treatment of Hematologic Malignancies
Treatment regimens including immunomodulatory agents or proteasome inhibitors could lead to development of peripheral neuropathy.
Current and Prospective Treatment Options for Waldenström Macroglobulinemia
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
Personalizing Intensive Therapy for Older Patients With Hematologic Cancers
Several factors need to be considered when choosing optimal therapy for older patients with hematologic malignancies, particularly when it comes to managing toxicity.
